Key result
Activation of the AT2 receptor with CGP42112 reduced TNF-α-stimulated ICAM-1 expression by approximately 53% via inhibition of NF-κB signaling, an effect partially mediated by ACE2.
This is the authors' abstract. We don't add key points for this paper.
ANG II type 2 receptor (AT2) and ANG I-converting enzyme 2 (ACE2) are important components of the renin-ANG system. Activation of AT2 and ACE2 reportedly counteracts proinflammatory effects of ANG II. However, the possible interaction between AT2 and ACE2 has never been established. We hypothesized that activation of AT2 increases ACE2 activity, thereby preventing TNF-α-stimulated ICAM-1 expression via inhibition of NF-κB signaling. Human coronary artery endothelial cells were pretreated with AT2 antagonist PD123319 (PD) or ACE2 inhibitor DX600 and then stimulated with TNF-α in the presence or absence of AT2 agonist CGP42112 (CGP). We found that AT2 agonist CGP increased both ACE2 protein expression and activity. This effect was blunted by AT2 antagonist PD. ICAM-1 expression was very low in untreated cells but greatly increased by TNF-α. Activation of AT2 with agonist CGP or with ANG II under concomitant AT1 antagonist reduced TNF-α-induced ICAM-1 expression, which was reversed by AT2 antagonist PD or ACE2 inhibitor DX600 or knockdown of ACE2 with small interfering RNA. AT2 activation also suppressed TNF-α-stimulated phosphorylation of inhibitory κB (p-IκB) and NF-κB activity. Inhibition of ACE2 reversed the inhibitory effect of AT2 on TNF-α-stimulated p-IκB and NF-κB activity. Our findings suggest that stimulation of AT2 reduces TNF-α-stimulated ICAM-1 expression, which is partly through ACE2-mediated inhibition of NF-κB signaling.
Answers are grounded in this paper and cite their sources.
Activation of the AT2 receptor suppresses TNF-α-induced ICAM-1 expression and NF-κB signaling in human coronary artery endothelial cells, an effect partially mediated by increased ACE2 activity.
No takes yet. Share an insight, caveat, or question.
Carretero et al. (2015) studied Vascular inflammation (in vitro). AT2 agonist CGP42112 vs. TNF-α alone was evaluated on TNF-α-mediated ICAM-1 expression (fold change) (p=<0.01). Activation of the AT2 receptor with CGP42112 reduced TNF-α-stimulated ICAM-1 expression by approximately 53% via inhibition of NF-κB signaling, an effect partially mediated by ACE2.
Synapse has enriched 10 related papers. Consider them for comparative context: